MMP-9, a Potential Target for Cerebral Ischemic Treatment

Author(s): Xue Dong, Yu-Ning Song, Wei-Guo Liu, Xiu-Li Guo

Journal Name: Current Neuropharmacology

Volume 7 , Issue 4 , 2009

Become EABM
Become Reviewer
Call for Editor


Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally remodel the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix degradation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Recently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor blockers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, propagation, and therapeutics of cerebral ischemic diseases.

Keywords: Matrix metalloproteinase-9 (MMP-9), cerebral ischemia, regulation, therapeutical target

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [269 - 275]
Pages: 7
DOI: 10.2174/157015909790031157
Price: $65

Article Metrics

PDF: 4